Status:

COMPLETED

Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)

Lead Sponsor:

Alpha-1 Foundation

Conditions:

Alpha-1 Antitrypsin Deficiency

Chronic Obstructive Pulmonary Disease

Eligibility:

All Genders

18+ years

Brief Summary

Alpha-1 antitrypsin deficiency (AATD) is considered a rare genetic cause of chronic obstructive pulmonary disease (COPD) and liver disease. Recent data has suggested that AATD is not as rare as origin...

Eligibility Criteria

Inclusion

  • Male and female adults at least 18 years of age able to understand and consent to the procedures of this protocol.
  • All races and ethnicities will be considered for this study.
  • Post-bronchodilator values for pulmonary function tests on the day of enrollment with an FEV1 \< 80% of predicted and FEV1/FVC \< 70% (at least GOLD stage II).
  • Subjects who have been tested for Alpha-1 in the past but do not know their genotype or phenotype may be included in this study.
  • Note: For the inclusion criteria the investigators will use the patient's GOLD status, based on percent predicted (FEV1 \< 80% of predicted); however, after sending the absolute value of FEV1 to the Data Coordinating Center (DCC) the DCC will calculate the percent predicted using a standardized formula (NHANES III). For sites that do not use this predicted formula, the results obtained at the DCC may differ from those used for subject enrollment. (For example, a subject found to have an FEV1 of \<80% at the study site could have an FEV1 \> 80% when the DCC recalculates it). Enrollment will be based on the percent predicted at each study site. If necessary, the data from this small number of outliers will be analyzed separately.

Exclusion

  • Subjects in whom post-bronchodilator spirometry is not performed.
  • Subjects whose ordering physician has specifically requested that his patients not be considered for enrollment.
  • Patients who have been tested for Alpha-1 in the past and know their genotype or phenotype.

Key Trial Info

Start Date :

January 1 2008

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 1 2010

Estimated Enrollment :

3457 Patients enrolled

Trial Details

Trial ID

NCT01419158

Start Date

January 1 2008

End Date

January 1 2010

Last Update

January 19 2012

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

University of California Los Angeles

Los Angeles, California, United States, 90095

2

National Jewish Medical and Research Center

Denver, Colorado, United States, 80206

3

University of Florida (Gainesville)

Gainesville, Florida, United States, 32610

4

University of Florida (Jacksonville)

Jacksonville, Florida, United States, 32209